Sourcing & GuidesAesthetic DevicesInjectables

【United State】G2GBio Unveils Long-Acting Dual/Triple Agonist Preclinical Data at ADA, Targeting Monthly Dosing for Obesity

Jun 8, 2026Local score 9.5

Source image preserved for article context.

Editor's note

This preclinical data from G2GBio, presented at ADA 2026, signals a potential breakthrough for buyers in the obesity treatment supply chain. The sourcing signal is strong, as the company’s InnoLAMP platform addresses a key regulatory and formulation hurdle for high-dose dual/triple agonists. Buyers should watch for clinical trial progress and licensing deals, which could reshape supply-chain risks for long-acting injectable partners and contract manufacturers.

G2GBio presented preclinical data at the American Diabetes Association (ADA) 2026 meeting in New Orleans, demonstrating its InnoLAMP drug delivery platform can enable monthly subcutaneous injections of high-dose dual and triple agonists like CagriSema, tirzepatide, and retatrutide. The results address a key formulation challenge for next-generation obesity therapies, signaling potential supply-chain opportunities for long-acting injectable partners and contract manufacturers.

Preclinical data highlights

In rodent studies, all three candidates showed less than 5% initial drug release within 24 hours and maintained stable blood concentrations for over 28 days. This pharmacokinetic profile supports once-monthly dosing, a significant improvement over current weekly injections.

Platform advantage for high-dose peptides

G2GBio's InnoLAMP platform can load peptide drugs at over 50% concentration, overcoming the volume limitations of subcutaneous injections for high-dose dual/triple agonists. This technology is critical for developing patient-friendly, long-acting formulations.

Market context

CagriSema (Novo Nordisk), tirzepatide (Eli Lilly), and retatrutide are among the most promising next-gen obesity treatments, with weight loss exceeding 20-25%. However, their high dose requirements have hindered long-acting SC formulation development.

What buyers should watch

Distributors and clinic buyers should monitor G2GBio's progress toward clinical trials and potential licensing deals. The InnoLAMP platform could become a key enabling technology for long-acting GLP-1-based therapies, affecting supply chains for prefilled syringes, cartridges, and contract development services.

Company statement

CEO Lee Hee-yong said, "Dual/triple agonists are challenging for SC formulation due to high drug loads. Our high-load technology achieved low initial burst and sustained efficacy, and we will continue focusing on competitive long-acting formulations that improve patient convenience and reduce side effects."

Source: Read the original report | Published: June 08, 2026